Literature DB >> 15278268

Procoagulant and fibrinolytic activity in ventilator-associated pneumonia: impact of inadequate antimicrobial therapy.

Ali A El-Solh1, Mifue Okada, Celestino Pietrantoni, Alan Aquilina, Eileen Berbary.   

Abstract

OBJECTIVE: To determine the homeostatic balance of patients with ventilator-associated pneumonia (VAP) with respect to the adequacy of antimicrobial therapy. DESIGN AND
SETTING: Descriptive observational study in a 12-bed medical intensive care unit in a university-affiliated hospital. PATIENTS: Twenty-nine patients with VAP documented by quantitative culture of bronchoalveolar secretions and a control group of eight mechanically ventilated patients.
METHODS: Serial bronchoalveolar lavage fluid (BALF) samples were assayed for prothrombin activation fragment (F1+2), thrombin-antithrombin (TAT) complex, fibrinolytic activity, urokinase-type plasminogen activator (u-PA), and plasminogen activator inhibitor type 1 (PAI-1) on days 1, 4, and 7 after VAP onset.
RESULTS: Pathogens isolated from patients with inadequate empirical antimicrobial coverage included methicillin-resistant Staphylococcus aureus (n=2), Pseudomonas aeruginosa (n=4), and Acinetobacter baumannii (n=1). Compared to those who received adequate antibiotic therapy, TAT, F1+2, and PAI-1 levels increased while u-PA levels remained unchanged. Despite antibiotic adjustment on day 4, TAT levels remained elevated in those who lacked adequate antimicrobial coverage and were significantly correlated with PaO(2)/FIO(2). The procoagulant activity was accompanied by a local depression of fibrinolytic capacity that was attributed mainly to increased BALF PAI-1 levels. Nonsurvivors showed significantly higher levels of TAT and PAI-1 than survivors. No significant correlation between the bacterial burden and the homeostatic derangements was documented.
CONCLUSIONS: The lung inflammatory response seems to promulgate a local procoagulant activity associated with hypoxemia in those with inadequate antibiotic therapy. The homeostatic derangement seems to be independent of the lung bacterial burden.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278268     DOI: 10.1007/s00134-004-2391-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  23 in total

Review 1.  Clinical approach to the critically ill, morbidly obese patient.

Authors:  Ali A El-Solh
Journal:  Am J Respir Crit Care Med       Date:  2004-03-01       Impact factor: 21.405

2.  Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.

Authors:  Anita W Rijneveld; Marcel Levi; Sandrine Florquin; Peter Speelman; Peter Carmeliet; Tom van Der Poll
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

Review 3.  Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996.

Authors:  D E Craven; K A Steger
Journal:  Semin Respir Infect       Date:  1996-03

4.  Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity.

Authors:  A Günther; M Kalinowski; A Elssner; W Seeger
Journal:  Am J Physiol       Date:  1994-11

Review 5.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

6.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Authors:  C M Luna; P Vujacich; M S Niederman; C Vay; C Gherardi; J Matera; E C Jolly
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

7.  Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII.

Authors:  S Idell; K Gonzalez; H Bradford; C K MacArthur; A M Fein; R J Maunder; J G Garcia; D E Griffith; J Weiland; T R Martin
Journal:  Am Rev Respir Dis       Date:  1987-12

8.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

9.  Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees.

Authors:  M Levi; T van Der POLL; H ten CATE; B Kuipers; B J Biemond; H M Jansen; J W ten CATE
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

10.  Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa.

Authors:  B J Biemond; M Levi; H ten Cate; H R Soule; L D Morris; D L Foster; C A Bogowitz; T van der Poll; H R Büller; J W ten Cate
Journal:  Thromb Haemost       Date:  1995-02       Impact factor: 5.249

View more
  7 in total

1.  Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation.

Authors:  Rogier M Determann; Julian L Millo; Chris S Garrard; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2006-04-14       Impact factor: 17.440

2.  Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis.

Authors:  Ali A El Solh; Milapchand Bhora; Lilibeth Pineda; Alan Aquilina; Laurie Abbetessa; Eileen Berbary
Journal:  Intensive Care Med       Date:  2005-11-12       Impact factor: 17.440

Review 3.  The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.

Authors:  Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

4.  Plasminogen activator inhibitor-type I gene deficient mice show reduced influx of neutrophils in ventilator-induced lung injury.

Authors:  Esther K Wolthuis; Alexander P J Vlaar; Jorrit-Jan H Hofstra; Joris J T H Roelofs; Vivian de Waard; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care Res Pract       Date:  2011-07-14

Review 5.  Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-12-18       Impact factor: 17.440

6.  Dexamethasone inhibits endotoxin-induced coagulopathy in human lungs.

Authors:  J Bartko; C Schoergenhofer; M Schwameis; N Buchtele; J Wojta; G Schabbauer; L Stiebellehner; B Jilma
Journal:  J Thromb Haemost       Date:  2016-10-24       Impact factor: 5.824

Review 7.  Intracellular and extracellular serpins modulate lung disease.

Authors:  D J Askew; G A Silverman
Journal:  J Perinatol       Date:  2008-12       Impact factor: 2.521

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.